Evaluation of adherence to a triple antiretroviral therapy in HIV-positive patients

European Journal of Internal Medicine

Volumn 10, Issue 4, 1999, Pages 202-205

  Abellán, Javier ^a   Garrote, Miriam ^a   Pulido, Federico ^a   Rubio, Rafael ^a   Costa, José R ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Adherence; Antiretroviral therapy; HIV; Viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; INDINAVIR; METHADONE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CELL COUNT; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PATIENT INFORMATION; QUESTIONNAIRE; VIRUS LOAD;

EID: 0033403971     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(99)00052-7     Document Type: Article

References (17)

1. Carpenter CC, Fischl MA, Hammer SMet al. Antiretroviral therapy for HIV infection in 1998. JAMA. 280:1998;78-86.
2. US Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1988;47(RR-05):43-82.
3. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos Pet al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 352:1998;1725-1730.
4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GAet al. New Engl J Med. 338:1998;853-860.
5. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. editors. Declining morbidity and mortality among patients with Advanced Human Inmunodeficiency virus infection. A randomized double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada, and Australia Study. JAMA 1998;279:930-937.
6. Fatkenheure G, Theisen A, Rockstroh Jet al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 11:1997;F113-F116.
7. Williams A, Friedland G. Adherence, Compliance and HAART. AIDS Clin Care 1997;9:51-55, 58.
8. Hecht FM Measuring HIV treatment adherence in clinical practice. AIDS Clin Care. 10:1998;57-59.
9. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo, Moore RD Self-reported antiretroviral therapy in injection drug users. JAMA. 280:1998;544-546.
10. Strathdee SA, Palepu A, Cornelisse PGAet al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 289:1998;547-549.
11. Bangsberg D, Tulsky JP, Hecht FM, Moss AR Protease inhibitors in the homeless. JAMA. 278:1997;63-65.
12. Knobel H, Carmona A, Grau S, Botet JP, Díez A Adherence and effectiveness of highly active antiretroviral therapy. Arch Intern Med. 158:1998;1953.
13. Eldred L, Gallant JE. Antiretroviral medication compliance: adherence in the era of triple-drug regimens. Northwestern University Reports on HIV/AIDS 1998;2:1-3, 7-8.
14. Rudd P, Byny RL, Zachary V, Loverde ME, Titus C, Mitchell WDet al. The natural history of medication compliance in a drug trial: limitations os pill counts. Clin Pharmacol Ther. 46:1989;169-176.
15. Chaisson RE, Keruly JC, Moore RD Race, sex, drug use and progression of HIV disease. New Engl J Med. 333:1995;751-756.
16. Mehta S, Moore RD, Graham NM Potential factors affecting adherence with HIV therapy. AIDS. 11:1997;1665-1670. (editorial).
17. Wainberg MA, Friedland G Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 279:1998;1977-1983.